...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Resverlogix Announces New Insights into the Mechanism of Apabetalone's Cardioprotective Benefit in Chronic Kidney Disease Patients

10BagR ... Boom!

And the real punch to the jewels is how close we were to getting the puck in the net in BoM, even with some obvious study flaws in retrospect. And also neglecting the benefit of an interim analysis. Followed by learning so much from BoM, in terms of even better Tx combinations, outcomes, endpoint targets, and gaining a rare and highly coveted BTD status ... and yet, no further meaningful advancement after nearly 4 years. 

It looks more like a company and leadership that knows they have something special, but no clue how to move it forward ... other than continuing to garnish the plate and hoping for positive interest and attraction.

I feel like we have a Ferrari, but no knows how to get it out of the garage, but instead they got it parked sideways and are banging off the garage walls trying get it out now.

If I didn't have so much riding on RVX/ABL, I would be belly laughing at them ... 

Share
New Message
Please login to post a reply